Add-On Memantine Treatment for Bipolar II Disorder Comorbid with Alcohol Dependence: A 12-Week Follow-Up Study
| Autor: | Liang-Jen Wang, Sheng Yu Lee, Shiou Lan Chen, I. Hui Lee, Jau-Shyong Hong, Po See Chen, Kao Ching Chen, Yun Hsuan Chang, San Yuan Huang, Tzu Yun Wang, Ru Band Lu, Nian-Sheng Tzeng, Yen Kuang Yang |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
Bipolar Disorder Alcohol Drinking Dopamine Agents Taiwan Medicine (miscellaneous) Alcohol Comorbidity Toxicology Young Mania Rating Scale Gastroenterology Article 03 medical and health sciences Bipolar II disorder chemistry.chemical_compound 0302 clinical medicine Antimanic Agents Memantine Internal medicine medicine Humans Bipolar disorder Depression (differential diagnoses) Valproic Acid business.industry Brain-Derived Neurotrophic Factor Alcohol dependence medicine.disease 030227 psychiatry Alcoholism Psychiatry and Mental health Treatment Outcome chemistry Diagnosis Dual (Psychiatry) Cytokines Drug Therapy Combination business 030217 neurology & neurosurgery Follow-Up Studies medicine.drug |
| Zdroj: | Alcoholism: Clinical and Experimental Research. 42:1044-1050 |
| ISSN: | 0145-6008 |
| Popis: | BACKGROUND: Bipolar disorder (BD), especially BD-II, is frequently comorbid with alcohol dependence. Because BD-II and alcohol dependence are neurodegenerative disorders, agents with anti-inflammatory and neurotrophic effects might provide effective therapy. We investigated whether add-on memantine to regular valproate (VPA) treatment ameliorated clinical symptoms, reduced alcohol use and cytokine levels, and increased plasma brain-derived neurotrophic factor (BDNF) in BD-II patients with comorbid alcohol dependence. METHOD: As a single-arm 12-week clinical trial, BD-II patients with comorbid alcohol dependence undergoing regular VPA treatments were given add-on memantine (5 mg/day). Symptom severity, alcohol use, cytokine (plasma tumor necrosis factor [TNF]-α and C-reactive protein [CRP], transforming growth factor β1 [TGF-β1], interleukin-8 [IL-8], IL-10), and plasma BDNF levels were regularly assessed. RESULTS: Mean within-group decreases in Hamilton Depression Rating Scale (HDRS) and Young Mania Rating Scale (YMRS) scores, alcohol use, CRP, BDNF, and IL-8 levels were significantly different from baseline after 12 weeks of treatment. We found no significant correlation between alcohol use levels and changes in HDRS or YMRS scores. The correlation between reduced alcohol use and reduced TGF-β1 level was significant (B = 0.003, p = 0.019). CONCLUSIONS AND RELEVANCE: BD-II comorbid with alcohol dependence might benefit from add-on memantine treatment, which significantly reduced clinical severity, alcohol use, and plasma cytokine levels, and increased BDNF levels. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text